| 12.03 0.08 (0.67%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.41 | 1-year : | 18 |
| Resists | First : | 13.19 | Second : | 15.41 |
| Pivot price | 10.58 |
|||
| Supports | First : | 10.2 |
Second : | 8.35 |
| MAs | MA(5) : | 12.09 |
MA(20) : | 10.24 |
| MA(100) : | 8.44 |
MA(250) : | 8.07  |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 77.4 |
D(3) : | 80.3 |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 13.52 | Low : | 5.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DAWN ] has closed below upper band by 22.4%. Bollinger Bands are 155.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.26 - 12.32 | 12.32 - 12.37 |
| Low: | 11.46 - 11.53 | 11.53 - 11.59 |
| Close: | 11.93 - 12.03 | 12.03 - 12.12 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Fri, 23 Jan 2026
Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with 90% Upside Potential - DirectorsTalk Interviews
Thu, 22 Jan 2026
Assessing Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Growth Outlook - simplywall.st
Wed, 21 Jan 2026
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking - simplywall.st
Tue, 20 Jan 2026
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 7.6% - Time to Buy? - MarketBeat
Fri, 16 Jan 2026
First Week of March 20th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Thu, 15 Jan 2026
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 85 (%) |
| Shares Short | 11,180 (K) |
| Shares Short P.Month | 9,500 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.38 |
| Profit Margin | -113.6 % |
| Operating Margin | -61 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | -57.6 % |
| Gross Profit (p.s.) | 1.16 |
| Sales Per Share | 1.3 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -120 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -7.92 |
| PEG Ratio | 0 |
| Price to Book value | 2.74 |
| Price to Sales | 9.24 |
| Price to Cash Flow | -10.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|